Publications by authors named "Kasra Khodadadi"
To evaluate the effectiveness of targeted therapy on preventing or treating COVID-19, in this study, we want to share our experience about 14 patients (nine women, five men; average age, 59 years) who were treated with targeted therapy due to their underlying malignant disorders in our center.
View Article and Find Full Text PDFRed cell distribution width, a predictive factor in immunocompromised patients with COVID-19: A comparison retrospective study between cancer and kidney transplant patients.
Eur J Transl Myol
June 2022
We aimed to review the records of cancer and kidney transplant patients of out of 1135 COVID-19 patients, who were referred to our hospital (Valiasr) in Zanjan, from March 16th, 2020, to June 11th, 2020. This was single-center, historical cohort study. Patients were divided into different subgroups and compared of disease outcomes.
View Article and Find Full Text PDFTrastuzumab, as a recombinant IgG1 kappa, is a humanized monoclonal antibody against human epidermal growth factor receptor 2. Accordingly, it is widely used in breast cancers at early and advanced stages. Dermatomyositis is a rare adverse event of trastuzumab therapy, which is not well documented yet.
View Article and Find Full Text PDFBackground: Recent studies have focused on the incidence rate and pattern of meningoencephalitis in the coronavirus disease 2019 (COVID-19).
Aim: This study aims to shed more light on the CSF pattern and clinical characteristics of meningoencephalitis COVID-19 patients in Zanjan, Iran.
Methods: Nine cases of laboratory and imaging confirmed COVID-19 were admitted to Valiasr Hospitals in Zanjan, Iran.
Article Synopsis
- - The study investigated the incidence of venous thromboembolism (VTE) in COVID-19 patients after they were discharged from the hospital, tracking 1,529 patients for at least 45 days through follow-up calls.
- - Out of those, 228 patients reported potential VTE symptoms, but only one was diagnosed with symptomatic pulmonary embolism (PE), leading to a low rate of symptomatic VTE of 0.2% within the study period.
- - The findings suggest that routine use of extended thromboprophylaxis after hospitalization for COVID-19 may not be beneficial, indicating that further randomized trials are needed to clarify this issue.